Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.

Vitiazeva V, Kattla JJ, Flowers SA, Lindén SK, Premaratne P, Weijdegård B, Sundfeldt K, Karlsson NG.

PLoS One. 2015 Jun 15;10(6):e0130197. doi: 10.1371/journal.pone.0130197. eCollection 2015 Jun 15.

2.

A genetic model for gallbladder carcinogenesis and its dissemination.

Barreto SG, Dutt A, Chaudhary A.

Ann Oncol. 2014 Jun;25(6):1086-97. doi: 10.1093/annonc/mdu006. Epub 2014 Apr 4. Review.

3.

Aberrant glycosylation as biomarker for cancer: focus on CD43.

Tuccillo FM, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A, Tassone P, Scala I, Buonaguro FM, Quinto I, Scala G.

Biomed Res Int. 2014;2014:742831. doi: 10.1155/2014/742831. Epub 2014 Feb 13. Review.

4.

Altered tumor-cell glycosylation promotes metastasis.

Häuselmann I, Borsig L.

Front Oncol. 2014 Feb 13;4:28. doi: 10.3389/fonc.2014.00028. eCollection 2014 Feb 13. Review.

5.

Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis.

Liu X, Yi C, Wen Y, Radhakrishnan P, Tremayne JR, Dao T, Johnson KR, Hollingsworth MA.

Cancer Res. 2014 Mar 1;74(5):1609-20. doi: 10.1158/0008-5472.CAN-13-2444. Epub 2013 Dec 26.

6.

Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas.

Do SI, Kim K, Kim DH, Chae SW, Park YL, Park CH, Sohn JH.

J Breast Cancer. 2013 Jun;16(2):152-8. doi: 10.4048/jbc.2013.16.2.152. Epub 2013 Jun 28.

7.

Mucin-type O-glycosylation during development.

Tran DT, Ten Hagen KG.

J Biol Chem. 2013 Mar 8;288(10):6921-9. doi: 10.1074/jbc.R112.418558. Epub 2013 Jan 17. Review.

8.

Enhanced epimerization of glycosylated amino acids during solid-phase peptide synthesis.

Zhang Y, Muthana SM, Farnsworth D, Ludek O, Adams K, Barchi JJ Jr, Gildersleeve JC.

J Am Chem Soc. 2012 Apr 11;134(14):6316-25. doi: 10.1021/ja212188r. Epub 2012 Mar 27.

9.

CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization.

Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D.

Cancer Res. 2011 Jun 1;71(11):3802-11. doi: 10.1158/0008-5472.CAN-11-0519. Epub 2011 Apr 11.

10.

Cathelicidins in inflammation and tissue repair: Potential therapeutic applications for gastrointestinal disorders.

Wu WK, Wong CC, Li ZJ, Zhang L, Ren SX, Cho CH.

Acta Pharmacol Sin. 2010 Sep;31(9):1118-22. doi: 10.1038/aps.2010.117. Epub 2010 Aug 2. Review.

11.

Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis.

Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, Yu LG.

Mol Cancer. 2010 Jun 18;9:154. doi: 10.1186/1476-4598-9-154.

12.

RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells.

Yamazoe S, Tanaka H, Sawada T, Amano R, Yamada N, Ohira M, Hirakawa K.

J Exp Clin Cancer Res. 2010 May 23;29:53. doi: 10.1186/1756-9966-29-53.

13.

An O-glycosyltransferase promotes cell adhesion during development by influencing secretion of an extracellular matrix integrin ligand.

Zhang L, Tran DT, Ten Hagen KG.

J Biol Chem. 2010 Jun 18;285(25):19491-501. doi: 10.1074/jbc.M109.098145. Epub 2010 Apr 6.

14.

Mucins in ovarian cancer diagnosis and therapy.

Chauhan SC, Kumar D, Jaggi M.

J Ovarian Res. 2009 Dec 24;2:21. doi: 10.1186/1757-2215-2-21.

15.

A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer.

Jia Y, Persson C, Hou L, Zheng Z, Yeager M, Lissowska J, Chanock SJ, Chow WH, Ye W.

Cancer Causes Control. 2010 Feb;21(2):313-21. doi: 10.1007/s10552-009-9463-3.

16.

Current status of mucins in the diagnosis and therapy of cancer.

Rachagani S, Torres MP, Moniaux N, Batra SK.

Biofactors. 2009 Nov-Dec;35(6):509-27. doi: 10.1002/biof.64. Review. Erratum in: Biofactors. 2012 Nov-Dec;38(6):478.

17.
18.

Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface.

Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, Yu LG.

Cancer Res. 2009 Sep 1;69(17):6799-806. doi: 10.1158/0008-5472.CAN-09-1096. Epub 2009 Aug 18.

19.

Recent insights into the biological roles of mucin-type O-glycosylation.

Tian E, Ten Hagen KG.

Glycoconj J. 2009 Apr;26(3):325-34. doi: 10.1007/s10719-008-9162-4. Epub 2008 Aug 10. Review.

20.

Alterations in mucin expression in ovarian mucinous tumors: immunohistochemical analysis of MUC2, MUC5AC, MUC6, and CD10 expression.

Hirabayashi K, Yasuda M, Kajiwara H, Itoh J, Miyazawa M, Hirasawa T, Muramatsu T, Murakami M, Mikami M, Osamura RY.

Acta Histochem Cytochem. 2008 Apr 26;41(2):15-21. doi: 10.1267/ahc.08008.

Supplemental Content

Support Center